IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
IDEXX LABORATORIES INC /DE
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$555.80−4.56 (-0.81%)
Close on Oct 19, 2026
- Market cap
- $44.08B
- P/E (TTM)
- 39.1
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
94.5%
74M of 79M shares
Institutional holders
1,300
115 new, 106 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 36 sales
Net sold $37.66M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 7,599,078 | 9.40% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Capital Management | 5,976,472 | 7.51% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IDXX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8,170,178 | 10.37% | $4.30B | −195,375 | 0.06% |
| Vanguard Capital Management LLC | 5,152,213 | 6.54% | $2.71B | −30,294 | 0.06% |
| Vanguard Portfolio Management LLC | 3,896,521 | 4.95% | $2.05B | −14,342 | 0.09% |
| State Street Corp | 3,748,660 | 4.76% | $1.97B | +74,475 | 0.06% |
| Invesco Ltd. | 3,611,416 | 4.58% | $1.90B | +261,739 | 0.15% |
| Geode Capital Management, LLC | 2,562,886 | 3.25% | $1.35B | −98,113 | 0.07% |
| Bamco Inc /Ny/ | 1,976,778 | 2.51% | $1.04B | +343,411 | 1.56% |
| Morgan Stanley | 1,356,103 | 1.72% | $713.91M | +40,149 | 0.04% |
| Bank of New York Mellon Corp | 1,193,343 | 1.51% | $628.22M | −311,189 | 0.10% |
| Arrowstreet Capital, Limited Partnership | 1,067,078 | 1.35% | $561.75M | +228,239 | 0.25% |
| Fundsmith LLP | 1,019,887 | 1.29% | $536.91M | −445,899 | 3.93% |
| Blair William & Co/Il | 918,556 | 1.17% | $483.56M | −27,780 | 1.26% |
| Northern Trust Corp | 918,137 | 1.17% | $483.34M | +6,244 | 0.06% |
| UBS Asset Management Americas Inc | 911,489 | 1.16% | $479.84M | +39,700 | 0.09% |
| FMR LLC | 822,643 | 1.04% | $433.07M | +539,667 | 0.02% |
| American Century Companies Inc | 808,358 | 1.03% | $425.55M | +208,427 | 0.19% |
| Capital Research Global Investors | 789,111 | 1.00% | $415.47M | +7,766 | 0.06% |
| JPMorgan Chase & Co | 755,791 | 0.96% | $405.05M | −24,091 | 0.02% |
| Principal Financial Group Inc | 743,246 | 0.94% | $391.30M | −137,943 | 0.19% |
| Goldman Sachs Group Inc | 738,708 | 0.94% | $388.89M | +21,787 | 0.03% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1,300 | 74M | 94.5% | 115 / 477 | 505 / 106 | 6M | 5M |
| Q1 2026 | 1,318 | 73M | 93.2% | 125 / 432 | 521 / 174 | 15M | 14M |
| Q4 2025 | 1,386 | 83M | 100.0% | 191 / 484 | 481 / 80 | 16M | 6M |
| Q3 2025 | 1,303 | 73M | 92.9% | 162 / 420 | 488 / 75 | 5M | 6M |
| Q2 2025 | 1,235 | 75M | 95.2% | 199 / 423 | 421 / 94 | 7M | 6M |
| Q1 2025 | 1,143 | 74M | 94.2% | 123 / 466 | 356 / 89 | 8M | 6M |
| Q4 2024 | 1,124 | 72M | 91.8% | 165 / 338 | 440 / 141 | 8M | 10M |
| Q3 2024 | 1,117 | 74M | 93.9% | 105 / 364 | 430 / 87 | 13M | 5M |
| Q2 2024 | 1,110 | 76M | 96.0% | 84 / 421 | 386 / 107 | 6M | 6M |
| Q1 2024 | 1,147 | 76M | 96.3% | 97 / 404 | 413 / 88 | 5M | 4M |
| Q4 2023 | 1,154 | 75M | 95.4% | 189 / 348 | 428 / 81 | 6M | 5M |
| Q3 2023 | 1,060 | 74M | 94.0% | 89 / 386 | 386 / 86 | 4M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of IDXX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,504,327 | 3.18% | $1.32B | 0.06% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 2,043,087 | 2.59% | $1.08B | 0.06% | Jun 30, 2026 |
| Vanguard Mid-Cap Index Fund | 1,709,209 | 2.17% | $899.80M | 0.40% | Jun 30, 2026 |
| Invesco QQQ Trust, Series 1 | 1,674,463 | 2.13% | $881.50M | 0.18% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 1,085,259 | 1.38% | $571.32M | 0.06% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 1,021,854 | 1.30% | $575.85M | 0.07% | May 31, 2026 |
| Vanguard Growth Index Fund | 942,289 | 1.20% | $496.06M | 0.13% | Jun 30, 2026 |
| Baron Partners Fund | 846,300 | 1.07% | $445.53M | 2.47% | Jun 30, 2026 |
| AMCAP Fund | 732,861 | 0.93% | $412.99M | 0.42% | May 31, 2026 |
| Vanguard Mid-Cap Growth Index Fund | 604,333 | 0.77% | $318.15M | 0.91% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 557,240 | 0.71% | $293.35M | 0.72% | Jun 30, 2026 |
| Vanguard Institutional Index Fund | 428,270 | 0.54% | $225.46M | 0.06% | Jun 30, 2026 |
| Vanguard U.S. Growth Fund | 425,415 | 0.54% | $239.73M | 0.50% | May 31, 2026 |
| iShares Russell Mid-Cap Growth ETF | 391,932 | 0.50% | $206.33M | 0.96% | Jun 30, 2026 |
| Invesco NASDAQ 100 ETF | 338,523 | 0.43% | $190.77M | 0.20% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jonathan Jay Mazelsky | President and CEO, Director | 83,803 | 0.11% | Mar 2, 2026 |
| Andrew Emerson | EVP, CFO and Treasurer | 4,507 | 0.01% | Aug 24, 2026 |
| George Fennell | Executive Vice President | 10,717 | 0.01% | Jun 2, 2026 |
| Sharon E. Underberg | EVP, GC & Corporate Secretary | 7,138 | 0.01% | Mar 5, 2026 |
| Nimrata Hunt | Executive Vice President | 18,301 | 0.02% | Mar 5, 2026 |
| Michael G. Erickson | Executive Vice President | 15,092 | 0.02% | Mar 3, 2026 |
| Michael Schreck | Executive Vice President | 2,123 | 0.00% | Feb 17, 2026 |
| Michael Perkins Johnson | Executive Vice President | 2,795 | 0.00% | Feb 17, 2026 |
| Martin Alexander Smith | Executive Vice President | 1,603 | 0.00% | Feb 17, 2026 |
| Michael Lane | Executive Vice President | 8,169 | 0.01% | Feb 17, 2026 |
| Brian P. McKeon | EVP, CFO and Treasurer | 49,600 | 0.06% | Feb 18, 2025 |
| Lawrence D. Kingsley | Director | 9,568 | 0.01% | Sep 9, 2026 |
| Joseph L. Hooley | Director | 325 | 0.00% | Aug 3, 2026 |
| Irene Chang Britt | Director | 208 | 0.00% | May 14, 2026 |
| Bruce L. Claflin | Director | 1,721 | 0.00% | May 14, 2026 |
| Sam Samad | Director | 0 | – | May 14, 2026 |
| Stuart Essig | Director | 2,236 | 0.00% | May 14, 2026 |
| Karen Peacock | Director | 102 | 0.00% | May 14, 2026 |
| Sophie V. Vandebroek | Director | 9,078 | 0.01% | May 14, 2026 |
| Daniel M. Junius | Director | 3,561 | 0.00% | May 14, 2026 |
| M. Anne Szostak | Director | 2,320 | 0.00% | May 11, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Lawrence D. Kingsley Director | Sep 4, 2026 | Sale | −2,203 | $532.08 | $1.17M | 9,568 |
| Lawrence D. Kingsley Director | Sep 4, 2026 | Option exercise | +2,203 | $114.17 | $251.52K | 11,771 |
| Andrew Emerson EVP, CFO and Treasurer | Aug 20, 2026 | Option exercise | +265 | $178.26 | $47.24K | 4,507 |
| Andrew Emerson EVP, CFO and Treasurer | Aug 20, 2026 | Tax withholding | −86 | – | – | 4,421 |
| Joseph L. Hooley Director | Jul 30, 2026 | Award | +49 | $558.80 | $27.38K | 325 |
| George Fennell Executive Vice President | Jun 1, 2026 | Option exercise | +639 | – | – | 10,717 |
| George Fennell Executive Vice President | Jun 1, 2026 | Tax withholding | −284 | $566.79 | $160.97K | 10,433 |
| Lawrence D. Kingsley Director | May 7, 2026 | Option exercise | +82 | – | – | 9,568 |
| Lawrence D. Kingsley Director | May 7, 2026 | Option exercise | +257 | – | – | 9,486 |
| M. Anne Szostak Director | May 7, 2026 | Option exercise | +257 | – | – | 519 |
| Daniel M. Junius Director | May 7, 2026 | Option exercise | +257 | – | – | 3,561 |
| Karen Peacock Director | May 7, 2026 | Option exercise | +101 | – | – | 102 |
| Joseph L. Hooley Director | May 7, 2026 | Option exercise | +158 | – | – | 276 |
| Sophie V. Vandebroek Director | May 7, 2026 | Option exercise | +257 | – | – | 905 |
| Joseph L. Hooley Director | Apr 30, 2026 | Award | +43 | $560.80 | $24.11K | 118 |
| Nimrata Hunt Executive Vice President | Mar 3, 2026 | Sale | −1,758 | $634.57 | $1.12M | 18,141 |
| Sharon E. Underberg EVP, GC & Corporate Secretary | Mar 3, 2026 | Option exercise | +197 | $505.53 | $99.59K | 7,138 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 27, 2026 | Option exercise | +197 | $505.53 | $99.59K | 83,803 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −3,660 | $658.92 | $2.41M | 91,254 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −1,343 | $656.85 | $882.15K | 97,774 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −1,488 | $655.85 | $975.90K | 99,117 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −1,111 | $654.63 | $727.29K | 100,605 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −1,171 | $653.68 | $765.46K | 101,716 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −1,669 | $652.49 | $1.09M | 102,887 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −2,859 | $659.75 | $1.89M | 88,395 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −1,200 | $661.10 | $793.32K | 87,195 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −1,000 | $662.16 | $662.16K | 86,195 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −2,589 | $663.04 | $1.72M | 83,606 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Option exercise | +23,326 | $141.60 | $3.30M | 106,932 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −1,281 | $650.67 | $833.51K | 105,651 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −1,095 | $651.49 | $713.38K | 104,556 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −2,860 | $657.84 | $1.88M | 94,914 |
| Nimrata Hunt Executive Vice President | Feb 26, 2026 | Sale | −2,693 | $661.54 | $1.78M | 19,899 |
| Michael G. Erickson Executive Vice President | Feb 19, 2026 | Option exercise | +483 | $206.94 | $99.95K | 14,712 |
| Michael G. Erickson Executive Vice President | Feb 19, 2026 | Option exercise | +817 | $178.26 | $145.64K | 14,229 |
| Michael G. Erickson Executive Vice President | Feb 19, 2026 | Option exercise | +719 | $141.60 | $101.81K | 13,412 |
| Michael G. Erickson Executive Vice President | Feb 19, 2026 | Option exercise | +183 | $544.08 | $99.57K | 14,895 |
| Michael G. Erickson Executive Vice President | Feb 19, 2026 | Option exercise | +197 | $505.53 | $99.59K | 15,092 |
| Michael G. Erickson Executive Vice President | Feb 17, 2026 | Sale | −40 | $629.86 | $25.19K | 12,693 |
| Michael G. Erickson Executive Vice President | Feb 17, 2026 | Sale | −689 | $629.09 | $433.44K | 12,733 |
| Michael G. Erickson Executive Vice President | Feb 17, 2026 | Sale | −2,694 | $628.22 | $1.69M | 13,422 |
| Michael G. Erickson Executive Vice President | Feb 17, 2026 | Sale | −1,288 | $626.26 | $806.62K | 16,116 |
| Michael G. Erickson Executive Vice President | Feb 17, 2026 | Sale | −204 | $625.24 | $127.55K | 17,404 |
| Michael G. Erickson Executive Vice President | Feb 17, 2026 | Sale | −456 | $623.76 | $284.43K | 17,608 |
| Michael G. Erickson Executive Vice President | Feb 17, 2026 | Option exercise | +4,180 | $178.26 | $745.13K | 18,064 |
| Michael G. Erickson Executive Vice President | Feb 17, 2026 | Option exercise | +1,191 | $141.60 | $168.65K | 13,884 |
| Sophie V. Vandebroek Director | Feb 17, 2026 | Sale | −519 | $628.56 | $326.22K | 648 |
| Sophie V. Vandebroek Director | Feb 17, 2026 | Sale | −945 | $628.65 | $594.07K | 1,167 |
| Sophie V. Vandebroek Director | Feb 17, 2026 | Option exercise | +945 | $333.90 | $315.54K | 2,112 |
| Michael Perkins Johnson Executive Vice President | Feb 14, 2026 | Tax withholding | −178 | $629.35 | $112.02K | 2,795 |
| Michael Perkins Johnson Executive Vice President | Feb 14, 2026 | Option exercise | +218 | – | – | 2,973 |
| Michael Perkins Johnson Executive Vice President | Feb 14, 2026 | Option exercise | +176 | – | – | 2,576 |
| Michael Perkins Johnson Executive Vice President | Feb 14, 2026 | Option exercise | +179 | – | – | 2,755 |
| Michael Schreck Executive Vice President | Feb 14, 2026 | Option exercise | +117 | – | – | 2,123 |
| Michael Schreck Executive Vice President | Feb 14, 2026 | Option exercise | +169 | – | – | 2,292 |
| Michael Schreck Executive Vice President | Feb 14, 2026 | Option exercise | +301 | – | – | 2,593 |
| Michael Schreck Executive Vice President | Feb 14, 2026 | Option exercise | +367 | – | – | 2,960 |
| Michael Schreck Executive Vice President | Feb 14, 2026 | Option exercise | +1,005 | – | – | 3,965 |
| Michael Schreck Executive Vice President | Feb 14, 2026 | Tax withholding | −876 | $629.35 | $551.31K | 3,089 |
| George Fennell Executive Vice President | Feb 14, 2026 | Option exercise | +55 | – | – | 9,878 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| D. Kingsley Lawrence Director | Sep 4, 2026 | 2,203 | $1.17M | Sep 4, 2026 | Stock Option Exercise |
| Anne Szostak Margaret Director | May 20, 2026 | 1,344 | $744.01K | May 20, 2026 | Acquired as compensation -- Restricted Stock Units |
| K. Hunt Nimrata Officer | Mar 3, 2026 | 1,758 | $1.12M | Mar 3, 2026 | Exercised Shares |
| J. Mazelsky Jonathan Officer, Director | Feb 26, 2026 | 23,326 | $15.34M | Feb 26, 2026 | Stock Option Exercise |
| K. Hunt Nimrata Officer | Feb 25, 2026 | 2,693 | $1.78M | Feb 25, 2026 | Exercised Shares |
| V. Vandebroek Sophie Director | Feb 17, 2026 | 1,464 | $920.29K | Feb 17, 2026 | Restricted Stock |
| G. Erickson Michael Officer | Feb 17, 2026 | 5,371 | $3.37M | Feb 17, 2026 | Stock Option Exercise |
| Fennell George Officer | Feb 10, 2026 | 11,345 | $7.34M | Feb 10, 2026 | Stock Option Exercise |
| K. Hunt Nimrata Officer | Nov 7, 2025 | 9,425 | $6.63M | Nov 7, 2025 | Stock Option Exercise |
| Anne Szostak Margaret Director | Aug 22, 2025 | 2,187 | $1.42M | Aug 22, 2025 | Stock Option Exercise |
| G. Erickson Michael Officer | Aug 12, 2025 | 407 | $264.53K | Aug 12, 2025 | Employee Stock Purchase Plan |
| K. Hunt Nimrata Officer | Aug 11, 2025 | 1,200 | $787.84K | Aug 11, 2025 | Exercised Shares |
| E. Underberg Sharon Officer | Aug 8, 2025 | 5,450 | $3.55M | Aug 8, 2025 | Stock Option Exercise |
| K. Hunt Nimrata Officer | Aug 6, 2025 | 7,143 | $4.50M | Aug 6, 2025 | Stock Option Exercise |
| J. Lane Michael Officer | Aug 6, 2025 | 8,411 | $5.28M | Aug 6, 2025 | Stock Option Exercise |